[1]杨瑞,丛顺地,张路.参苓白术散加减治疗肺癌术后化疗患者临床疗效观察[J].西部中医药,2026,39(03):165-169.[doi:10.12174/j.issn.2096-9600.2026.03.31]
　YANG Rui,CONG Shundi,ZHANG Lu.Observation on Curative Effects of Modified Shenling Baizhu Powder in Treating Patients with Lung Cancer after Chemotherapy[J].Western Journal of Traditional Chinese Medicine,2026,39(03):165-169.[doi:10.12174/j.issn.2096-9600.2026.03.31]
点击复制

参苓白术散加减治疗肺癌术后化疗患者临床疗效观察()

《西部中医药》[ISSN:2096-9600/CN:62-1204/R]

卷:
39
期数:
2026年03期
页码:
165-169
栏目:
衷中参西
出版日期:
2026-03-15

文章信息/Info

Title:
Observation on Curative Effects of Modified Shenling Baizhu Powder in Treating Patients with Lung Cancer after Chemotherapy
作者:
杨瑞, 丛顺地, 张路
菏泽市中医医院，山东 菏泽 274000
Author(s):
YANG Rui, CONG Shundi, ZHANG Lu
Heze Hospital of Traditional Chinese Medicine, Heze 274000, China
关键词:
肺癌术后; 参苓白术散; 肺功能; 肿瘤标志物
Keywords:
after the surgery of lung cancer; powder; lung function; tumor markers
分类号:
R273
DOI:
10.12174/j.issn.2096-9600.2026.03.31
文献标志码:
B
摘要:
目的探讨参苓白术散加减对肺癌术后化疗患者肺功能及肿瘤标志物的影响，为临床治疗提供依据。 方法选取80例中晚期非小细胞肺癌（non-small cell lung cancer，NSCLC）肺脾气虚证化疗患者为研究对象，随机分为对照组和观察组，各40例。两组患者均行肺癌根治术，对照组术后采用GP方案（吉西他滨联合顺铂）化疗，观察组在对照组基础上加用参苓白术散治疗。比较两组患者的临床疗效、中医症状积分、肺功能指标［用力肺活量（forced vital capacity，FVC）、第1秒用力呼气容积（forced expiratory volume in one second，FEV1）、最大通气量（maximal voluntary ventilation，MVV）］、血清肿瘤标志物［癌胚抗原（carcinoembryonic antigen，CEA）、细胞角蛋白19片段（cytokeratin 19 fragment，CYFRA21-1）、鳞状细胞癌抗原（squamous cell carcinoma antigen，SCC）］、生活质量评分及不良反应发生率。 结果观察组总有效率［75.0%（30/40）］高于对照组［60.00%（24/40）］（P＜0.05）；治疗后，两组症状积分均较治疗前降低，且观察组低于对照组（P＜0.05）；治疗后，两组FVC、FEV1、MVV均较治疗前升高，且观察组高于对照组（P＜0.05）；治疗后，两组血清CEA、CYFRA21-1、SCC水平均较治疗前降低（P＜0.05），且观察组低于对照组（P＜0.05）；治疗后，两组生理功能、躯体疼痛、社会功能、精神健康、总体健康评分均较治疗前升高，且观察组高于对照组（P＜0.05）；治疗期间，观察组肝肾功能异常、恶心呕吐、血小板减少、白细胞减少的发生率均低于对照组（P＜0.05）。 结论参苓白术散加减可有效改善肺癌术后化疗患者的临床症状、肺功能，降低肿瘤标志物水平，提高生活质量，并减少化疗相关不良反应。
Abstract:
ObjectiveTo produce the reference for clinical therapy by exploring the effects of modified Shenling Baizhu powder on lung function and tumor markers in patients with lung cancer after chemotherapy. MethodsEighty advanced NSCLC patients undergoing chemotherapy were chosen as the research subjects, and they were randomized into the control group and the observation group with 40 cases in each. Radical resection of lung cancer was conducted in the two groups, the control group received chemotherapy with the GP regimen (gemcitabine combined with cisplatin) after surgery, and the observation group was treated with Shenling Baizhu powder based on the therapy of the control group. To compare therapeutic effects, TCM symptom scores, the indexes of lung function including FVC, FEV1, and MVV, serum tumor markers covering CEA, CYFRA21-1 and SCC, the scores of quality of life and the incidences of adverse reaction between the two groups. ResultsTotal effective rate of the observation group was [75.0%(30/40)], higher than [60.00%(24/40)] of the control group (P<0.05); after the treatment, the symptom scores were lower than these before the treatment, and the observation group was lower than the control group (P<0.05); after the treatment, FVC, FEV1, and MVV were elevated than these before the treatment, and the observation group was higher than the control group (P<0.05); after the treatment, the two groups demonstrated the decreased levels of CEA, CYFRA21-1 and SCC compared with these before the treatment (P<0.05), and the observation group was lower than the control group (P<0.05); after the treatment, the two groups exhibited the increased scores in physical functioning, bodily pain, social functioning, mental health and general health, and the observation group was higher than the control group (P<0.05); during therapeutic period, the incidences of liver and kidney dysfunction, nausea and vomiting, thrombocytopenia, and leukopenia of the observation group were lower than these of the control group (P<0.05). ConclusionModified Shenling Baizhu powder could effectively improve clinical symptoms and lung function of the patients with lung cancer after chemotherapy, lower the levels of tumor markers, improve quality of life, and alleviate chemotherapy-related adverse reactions.

相似文献/References:

[1]周胜涟,龚辉,陈州华.健脾渗湿法治疗放射性肠炎的临床观察[J].西部中医药,2014,27(03):102.
　ZHOU Shenglian,GONG Hui,CHEN Zhouhua.Curative Observation on Therapy for Radioactive Enteritis by the Method of Spleen-invigorating and Dampness-eliminating[J].Western Journal of Traditional Chinese Medicine,2014,27(03):102.
[2]贾晓东,鱼涛△.温中散外敷热疗法配合参苓白术散内服治疗脾胃虚弱腹泻型肠易激综合征疗效观察[J].西部中医药,2018,31(11):81.
　JIA Xiaodong,YU Tao.Clinical Observation on Heat Therapy of WenZhong Powder for External Application and Oral Administration of ShenLing BaiZhu Powder in the Treatment for IBS-D of Spleen-stomach Weakness Pattern[J].Western Journal of Traditional Chinese Medicine,2018,31(03):81.
[3]李晓彤,李家立,曹志群,等.基于网络药理学和分子对接技术探讨参苓白术散治疗功能性腹泻的作用机制[J].西部中医药,2026,39(01):96.[doi:10.12174/j.issn.2096-9600.2026.01.17]
　LI Xiaotong,LI Jiali,CAO Zhiqun,et al.Mechanism of Shenling Baizhu Powder in Treating Functional Diarrhea Based on Network Pharmacology and Molecular Docking Technology[J].Western Journal of Traditional Chinese Medicine,2026,39(03):96.[doi:10.12174/j.issn.2096-9600.2026.01.17]
[4]顾东彦,王子雯,许孟月,等.基于网络药理学及分子对接探讨参苓白术散治疗特应性皮炎的作用机制[J].西部中医药,2025,38(08):45.[doi:10.12174/j.issn.2096-9600.2025.08.10]
　GU Dongyan,WANG Ziwen,XU Mengyue,et al.Mechanism of Shenling Baizhu Powder in the Treatment of Atopic Dermatitis Based on Network Pharmacology and Molecular Docking[J].Western Journal of Traditional Chinese Medicine,2025,38(03):45.[doi:10.12174/j.issn.2096-9600.2025.08.10]
[5]陈茜,刘伟,姜华,等.参苓白术散联合氨茶碱片治疗慢性阻塞性肺疾病的临床疗效[J].西部中医药,2020,33(06):95.[doi:10.12174/j.issn.1004-6852.2020.06.25]
　CHEN Xi,LIU Wei,JIANG Hua,et al.A Study on Clinical Effects of Shenling Baizhu Powder Combined with Aminophylline Tablets in Treating COPD[J].Western Journal of Traditional Chinese Medicine,2020,33(03):95.[doi:10.12174/j.issn.1004-6852.2020.06.25]
[6]李丽梅,王永强.参苓白术散联合美沙拉嗪治疗溃疡性结肠炎临床观察[J].西部中医药,2021,34(10):124.[doi:10.12174/j.issn.2096-9600.2021.10.31]
　LI Limei,WANG Yongqiang.Clinical Observation on Shenling Baizhu Powder and Mesalazine in Treating Ulcerative Colitis[J].Western Journal of Traditional Chinese Medicine,2021,34(03):124.[doi:10.12174/j.issn.2096-9600.2021.10.31]
[7]王思霖,孙志广.参苓白术散加减治疗功能性消化不良临床疗效Meta分析[J].西部中医药,2024,37(08):59.[doi:10.12174/j.issn.2096-9600.2024.08.15]
　WANG Silin,SUN Zhiguang.Clinical Effects of Modified Shenling Baizhu Powder in the Treatment of Functional Dyspepsia: A Meta-analysis[J].Western Journal of Traditional Chinese Medicine,2024,37(03):59.[doi:10.12174/j.issn.2096-9600.2024.08.15]

备注/Memo

备注/Memo:
山东省自然科学基金（ZR2021QH318）。杨瑞（1987—），女，主管药师。研究方向：中药学。
更新日期/Last Update: 2026-03-15